Philippe ROCHIGNEUX

Associate Professor

Aix-Marseille University
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Philippe Rochigneux is an Assistant Professor at Aix-Marseille University, France. His research focuses on immunology, particularly in the context of cancer therapies and immune checkpoint inhibitors. Recent publications include studies on the antitumor profiles of Vγ9Vδ2 T cells and the clinical parameters associated with immune checkpoint inhibitors in cancer treatment. He is also involved in investigating the effects of immune therapies on thyroid function and the psychosocial aspects of cancer treatment.

Articles (17)

Year:

2026

PURPOSE For elderly patients with pancreatic ductal adenocarcinoma (PDAC), FOLFIRINOX (FFX) is often contraindicated due to frequent grade III adverse events (AEs) limiting available data on this population. MATERIALS AND METHODS This retrospective single-center study identified patients older than70 years treated with FFX for PDAC (2011-2022). Tumor, G8 score calculation (score 80% of cases. Median FFX exposure was four cycles in mPDAC and 4.5 in nmPDAC. Overall, 56% experienced toxicity, including two treatment-related deaths. Frequent grade ≥3 AEs included infections (26%), nausea/vomiting (22%), and diarrhea (18%). Early toxicity within 2 months was associated with worse OS. Factors linked to toxicity included metastatic status (hazard ratio [HR], 2.41) and psychiatric comorbidities (HR, 6.96), while cardiovascular disease (HR, 0.35) and history of cancer (HR, 0.22) were protective. In nmPDAC, multidimensional geriatric assessment (MGA) reduced toxicity in G8 ≤ 14 patients. CONCLUSION FFX is feasible in highly selected elderly patients with PDAC. Severe toxicity remains frequent and proactive supportive care—including MGA in cases of G8 ≤ 14—to avoid early severe toxicity that impact significantly survival.

Year:

2026

Vγ9Vδ2 (TCRVγ9+ TCRVδ2+) T cells are promising immunotherapeutic targets with effective antitumor properties in both in vitro and preclinical models of triple-negative breast cancer (TNBC). However, no information about their potential role in the context of human TNBC progression and response to immunotherapy has been reported. One key reason for this is the scarcity of Vγ9Vδ2 T-cell infiltrates relative to their Vδ1 (TCRVδ1+) and αβCD8 (TCRαβ+ CD8αβ+) T-cell counterparts. We provide comprehensive single-cell profiling of Vγ9Vδ2 T cells from patients with TNBC, prior to and following PD-(L)1 blockade therapy. We report that baseline Vγ9Vδ2 T-cell infiltrate expressing a unique cytotoxic type I phenotype could be associated with improved survival in patients with TNBC. Vγ9Vδ2 T cells harboring characteristics of enhanced antitumor activity (KLRC1+) were further associated with improved response to PD-(L)1 blockade therapy in patients with TNBC. Vγ9Vδ2 T cells had low expression levels of T-cell exhaustion (PD-1LowTOXLow) and T-cell receptor signaling hallmarks compared with Vδ1 and αβCD8 T cells, along with skewed differentiation profiles toward early effector memory phenotypes, both before and after anti–PD-1 therapy in TNBC tumors. Consistently, we observed limited activity of anti–PD-1 on tumor-infiltrating Vγ9Vδ2 T cells. In vitro, the use of anti–butyrophilin-3A antibodies in addition to anti–PD-1 reinvigorated the cytotoxic type I functions of peripheral Vγ9Vδ2 T cells from patients with breast cancer. Together, these data provide a rationale for Vγ9Vδ2 T cell–based combination therapy in patients with TNBC.

Year:

2025

PURPOSE Immune checkpoint inhibitor (ICI)-induced thyroid dysfunction is a common endocrine immune-related adverse event. Although rates during therapy are well documented, data on post-treatment thyroid dysfunction are limited. We hypothesized that post-ICI thyroid dysfunction is under-recognized because of inadequate surveillance. METHODS A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted. Clinically acted-upon thyroid dysfunction (diagnosis or thyroid-directed medication) was evaluated before, during, and after ICI therapy, alongside rates of thyroid laboratory surveillance. RESULTS Clinically acted-upon thyroid dysfunction occurred in 8.1% (294/3,626) during treatment and 4.4% (159/3,626) after treatment. Among the 1,170 patients with post-ICI thyroid laboratory results and no prior dysfunction, 11.6% (136/1,170) developed post-ICI thyroid dysfunction. However, 48.6%% (1,764/3,626) had no post-ICI thyroid laboratory results. Thirty percent of patients with abnormal thyroid stimulating hormone (TSH) values and no clinically acted-upon thyroid dysfunction before therapy discontinuation subsequently developed clinically acted-upon thyroid dysfunction, and the rate of post-ICI clinically acted-upon thyroid dysfunction was higher in patients who received 9 or less months of ICI therapy. CONCLUSION Post-ICI thyroid dysfunction is frequent, with 11.6% of monitored patients being affected, and patients with abnormal TSH before ICI discontinuation and those who received treatment for 9 months or less may benefit from more stringent post-ICI surveillance.

Year:

2025

Year:

2025

Year:

2025

Objectives Immune Checkpoint Inhibitors (ICI) are nowadays a cornerstone of anti-cancer treatments. However, the wide spectrum of immune-related adverse events (irAEs) represents a challenge in the oncological practice. Our objective is to document rare complications of ICI to help the community of onco-immunologists. Methods We reported the case of a severe myositis mimicking bulbar palsy treated in our Medical Oncology Department together with Internal Medicine Department. We present the clinical work-up (neurological exam, capillaroscopy) and the diagnostic tests (myositis specific and associated antibodies, nerve conduction study, electromyography) leading to this diagnosis. We also discussed the elimination of differential diagnoses (notably with normal MRI and cerebrospinal fluid analysis) and finally the clinical management of this severe irAE. Results A 57 years woman presented multiple sub-diaphragmatic adenopathies related with an advanced melanoma of unknown primary. She started a treatment with Ipilimumab (Ipi, anti CTLA-4) and Nivolumab (Nivo, anti PD-1) and presented at day 10 a grade IV myositis mimicking bulbar palsy with dysphonia, dysarthria and aphagia. In a multidisciplinary setting, she was treated with IV corticosteroids (methylprednisolone 1 mg/kg started at day 10, with a progressive decrease until 1 mg of prednisone in March 2024), IV immunoglobulins started at day 18 (1.5 g/kg in 2 days, administered monthly, with a progressive decrease and a cessation in June 2022), enteral nutrition, speech therapy and physical therapy, with noticeable improvement. After 4 years of follow-up, and only one infusion of Ipi/Nivo, the melanoma is still in complete response. Conclusion We report an ICI-induced severe myositis mimicking bulbar palsy after the administration of Ipi/Nivo. The diagnosis and clinical care management of this rare complication requires a multi-disciplinary work-up.

Year:

2025

Year:

2025

Background: Virus-associated tumors, characterized by immune evasion and angiogenic signaling, remain a therapeutic challenge. Human papillomavirus (HPV)-associated cancers such as cervical, anal, and oropharyngeal cancers represent a significant subset of virus-associated tumors and are characterized by immune evasion mediated by viral oncoproteins such as E6 and E7. Toll-like receptor 7/8 (TLR7/8) agonists such as EIK1001 have been shown to activate innate immune pathways, enhancing antigen presentation and inducing a robust adaptive immune response. This is particularly relevant in HPV-related tumors, where viral oncoproteins E6 and E7 suppress immune surveillance. By targeting TLR7/8, EIK1001 may overcome this immune suppression, priming the tumor microenvironment for synergistic effects with immune checkpoint blockade. Additionally, stereotactic radiation therapy of a metastatic site can enhance immunotherapy efficacy by inducing immunogenic cell death, promoting the release of tumor antigens, and facilitating systemic immune activation (the abscopal effect). Methods: This phase II trial included 47 patients with metastatic virus-associated tumors across 10 sites between June 2021 and July 2023. Treatment comprised atezolizumab (1200 mg IV every 3 weeks), EIK1001 (0.75 mg/m2 IV on a weekly schedule for 9 weeks, then every 3 weeks), and stereotactic radiotherapy (27-60 Gy in 3-5 fractions to a metastatic site). Primary endpoint was disease control rate (DCR) at 24 weeks per RECIST v1.1. at 24 weeks per RECIST v1.1. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), safety, and biomarkers of immune activation (proteomics and spatial transcriptomics). Results: Forty-one patients with virus-associated tumors were enrolled between June 2021 and July 2023. The majority (85%) had HPV-related tumors, including cervical (40%), anal (30%), and oropharyngeal (15%) cancers. At 24 weeks, the DCR was 56.1% (90% CI: 42.1%-69.4%), with an ORR of 19.5% (90% CI: 10.1%-32.5%). Median PFS was 2.6 months (95% CI: 1.4-2.8), and median OS was 10.4 months (95% CI: 6.9-19.0). The most common Grade 3/4 treatment-related adverse events were fatigue (10%), diarrhea (8%), and pneumonitis (5%). Proteomic analyses of plasma demonstrated significant upregulation of immune effector proteins, indicating systemic immune activation. Spatial transcriptomics on tumor biopsies revealed enhanced T-cell infiltration and reprogramming of the tumor microenvironment, correlating with clinical responses. Conclusions: The combination of atezolizumab, EIK1001, and radiotherapy met its primary endpoint of disease control rate at 24 weeks, underscoring the potential of this regimen. in virus-associated tumors, particularly HPV-related cancers. Biomarker analyses support the immunogenic potential of this regimen, suggesting a paradigm shift in treating immunologically ‘cold’ virus-associated tumors. Further investigations will explore predictive biomarkers and refine patient selection. Citation Format: Antoine Italiano, Carlos Gomez-Roca, François Ghiringhelli, Jean-Philippe Metges, Philippe Rochigneux, Aurelien Carnot, Florian Estrade, Marie-Paule Sablin, Pierre-Emmanuel Brachet, Nicolas Isambert, Jade Dupin, Sophie Cousin, Jean-Philippe Guegan, Alban Bessede, Marina Pulido, Paul Sargos. Immunity induction with atezolizumab, EIK1001, and radiotherapy in virus-associated tumors: Results of the AGADIR Trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT129.

Year:

2025

Background While the use of chemotherapy near the end of life (EOL) has been identified as a relevant criterion for assessing quality of cancer care and has been estimated as non-beneficial, a trend of aggressiveness in cancer care during the last period of life remains. Both patients’ sociodemographic characteristics and physicians’ practice setting are associated with this use. The role of patients’ psychosocial characteristics has however been understudied. The objectives were to study oncologists’ intention to recommend chemotherapy or therapeutic abstention in an EOL patient’s case and to examine the factors associated with this decision. Methods A clinical vignette-based questionnaire survey was conducted. While the case presented to the participating oncologists of a patient with EGFR-mutated lung cancer, progressing after osimertinib, ECOG 3, with leptomeningeal disease (N = 146), was strictly equivalent in terms of medical aspects and age, 4 patients’ non-medical characteristics were manipulated: gender, marital status, parenthood, and psychosocial characteristics (“nice” patients, patients “making strong demands,” or control patients). Results 77.4% of the oncologists surveyed stated that they would recommend chemotherapy in this situation. Only scenarios with nice patients or patients making strong demands were associated with less recommendation of chemotherapy (70.8% for the nice/making strong demands scenarios together vs 87.7%, for the control scenario P = .017). Medical oncologists with previous experience of similar cases were also less keen to recommend chemotherapy (73% vs 100%, P = .007). Of the 76.7% of respondents declaring that they would think of other therapeutic options, 49.1% mentioned “other treatments” without mentioning palliative care. Conclusion Developing physicians’ awareness of the psychosocial aspects at stake in their medical decisions in these sensitive situations may improve EOL care.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (12)

Brice Gaudilliere

Associate Professor

Stanford University

UNITED STATES
View details

Léa Restivo

Assistant professor

Aix-Marseille University

FRANCE
View details

François Bertucci

Professor

Institut Paoli-Calmettes

FRANCE
View details

Jonathan W. Goldman

Associate Professor

UCLA

UNITED STATES
View details

Aaron Lisberg

University of California, Los Angeles

UNITED STATES
View details

Julien Mancini

-

FRANCE
View details

gilles houvenaeghel

Institut Paoli-Calmettes

FRANCE
View details

Sandrine de Montgolfier

Université Paris-Est Créteil Val de Marne

FRANCE
View details

daniel olive

Professeur des Universités-Praticien Hospitalier

Aix-Marseille University

FRANCE
View details

Anthony Gonçalves

Aix-Marseille University

FRANCE
View details

Edward B. Garon

University of California

UNITED STATES
View details

Francesca Mininel

Institut Paoli-Calmettes

FRANCE
View details